



Monday, 8 February 2010

STATEMENT OF INTENT FROM MAJOR INTERNATIONAL FMCG COMPANY

OBJ Limited (ASX: OBJ) is pleased to advise that it has received a Statement of Intent from a global FMCG (Fast Moving Consumer Goods) company in regards to an ongoing product development program utilising OBJ's ETP and DP technologies.

This FMCG company has permitted the release of the following statement:

"OBJ is continuing to work with a major healthcare company to develop a product to enhance the delivery of one of their key therapeutic agents"

The Company is pleased with the rapid progression of this program and will continue to keep shareholders updated.

Background

In 2007 OBJ executed a Collaboration Agreement with the major international FMCG company to explore the use of ETP and DP with two compounds for over-the-counter (OTC) use. This initial program was completed in March 2008 and in December 2008 the Company announced a second and larger technology optimization program, to be conducted in the USA at a facility operated by Azopharma Contract Services Inc. OBJ received approximately US\$335,000 for the program. The outcomes of that program were summarized in the release to shareholders in October 2009 and indicated that the Company's technology had achieved the FMCG company's stated objectives.

Since that time OBJ has continued to work with the FMCG company in the development of a product to enhance the delivery of one of their key therapeutic agents, and the Statement of Intent represents a continuation of that relationship.

- Ends -

For more information:

Mr Glyn Denison Director

P +618 9443 3011

E info@obj.com.au

W www.obj.com.au

About OBJ:

OBJ Ltd is an early stage drug and cosmetic delivery company focused on the development and commercialization of transdermal and transmembrane patches and applicator technologies. OBJ develops low-cost, high-performance patch and applicator products and undertakes partner funded developments using the Company's platform of magnetic enhanced drug delivery technologies. OBJ's business focus is the development of new products for supply or licencing and providing feasibility assessments, patch formulations, testing and intellectual property development services to partner companies.



About OBJ's Technologies

OBJ's proprietary drug delivery platform utilizes magnetic field and magnetic micro-array processes to enhance the delivery of therapeutic and beneficial compounds through the skin, tooth, hair and other biological barriers. OBJ's technologies have been shown in multi-centred university studies and independent commercial evaluations to enhance transdermal drug delivery of a wide a wide range of commercially significant drugs and peptides used in the pharmaceutical, dermatology, cosmetic and consumer healthcare sectors.